UBS Group
RLM

UBS Group’s Realm Therapeutics plc American Depositary Shares RLM Stock Holding History

UBS Group’s Portfolio RLM Stock Details RLM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,558
Closed -$7K – 8569
2019
Q2 		$7K Buy
2,558
+2,383
+1,362% +$7.87K ﹤0.01% 7293
2019
Q1 		$1K Sell
175
-374
-68% -$1.05K ﹤0.01% 7643
2018
Q4 		$1K Sell
549
-1,311
-70% -$3.24K ﹤0.01% 7964
2018
Q3 		$6K Buy
+1,860
New +$7.98K ﹤0.01% 7451

UBS Group's RLM Position: Q3 2019 in Review

UBS Group sold out of Realm Therapeutics plc American Depositary Shares (RLM) in Q3 2019, closing a stake of 2,558 shares — an estimated $7K sold.

UBS Group first reported a position in RLM in Q3 2018 and held it in 4 quarters. The position peaked at $7K in Q2 2019. 0 funds tracked by Wall St. Rank hold RLM as of Q3 2019.

  • UBS Group reported no remaining Realm Therapeutics plc American Depositary Shares position as of Q3 2019 after selling out during the quarter.
  • UBS Group sold 2,558 Realm Therapeutics plc American Depositary Shares shares in Q3 2019, an estimated $7K.
  • UBS Group first reported a position in Realm Therapeutics plc American Depositary Shares in Q3 2018 and held it in 4 quarters.
  • UBS Group's Realm Therapeutics plc American Depositary Shares position peaked at $7K in Q2 2019.
  • 0 funds tracked by Wall St. Rank held Realm Therapeutics plc American Depositary Shares as of Q3 2019.

Based on UBS Group's 13F filing for Q3 2019, filed 14 Nov 2019.